1. ⁩ ⁦⁩ in Cambridge study sensors on patients contact dermatitis patients sensors monitor movement text mining sensation reported by patients with sensors trajectory monitored drug device external partnership

  2. ⁩ ⁦ new drug: Biotech in Scripps, CA and another in Cambridge, MA and ⁦⁩ as Pharma collaboration with biotech Partnership with UPenn with Duke, NC agility in small co scale in Pharma

  3. ⁩ ⁦ and Medical community decide on directions for surrogate followed by survival NASH redefine NEW drug innovations will move faster Vaccine for NASH growing obesity population Network for collaboration

  4. ⁩ immunicity correlated confirm benefit in based study patient to benefit early on while cost benefit be known later inflammatory indicators across diseases JAKS inhibitors which drug for which patient

  5. ⁩ ⁦⁩ redefine by genomics clinical trials on patients with Gene expression 150 patients 60% improve rate new drug approved in 2011 in oncology how sustain innovation by cost effective trials? Patient selection

  6. Mikael Dolsten R&D budget for contribution capital allocation focus on deep expertise in multiple drugs in multiple indications Lipitor dependence ends patent expiration

  7. only by knowing both one can develop applications in vs questions are the hard part vs expertise needed for structural models type of data collected may not be best

  8. for idiopathic fibrosis using CONNECTION OF DRUG AND DISEASE known after development, pharma needs that BEFORE a drug is developed, clinics based on BRCA for treatment, finding binding targets/drug

  9. for patients goals apply right approach to care right drug respond to therapy is a HC goal combined with patient goals

  10. @FoundationMedicine in 7 days genomic data, clinical data and patient of patient took place in clean data sets are a must for patient total clinical profile

  11. COHORT is assisted by for clinical trials of rare types of cancers on small population of patients. Synthetic data compared with observed data for can get wrong results by using

  12. @FoundationMedicine sequenced 200,000 Cancer patients genome use data to Target positive predicted responders to accelerate clinical trials. use of on genomic data for

  13. @KatrineBosley @EditasMedicine Valuation for 23andme? Each pool of capital has different investors been attracted

  14. @JohnMaraganore @ALNYLAMPHARMACEUTICALS In 16 years rained $4Billion and expenses $2.5Billion – still not profitable – that what it takes

  15. @JeanFrancisFormela Science is extraordinary A lot of capital and very many tech ventures over supply of capital accelerates the business More capital is better, what to invest is critical

  16. US is not the only player, CANADA’ universal payer system made major strides lung cancer experienced development of 50 drug base on tumor type predict likelihood drug resistance BR CA patient which not require therapy

  17. @RajuKucherlapati Integration of EMR Partners leader missing link is integration of Genomic dat aat the patient level with clinical dat of patients Patients will manage their 23andme data PM is global vs access to care

  18. @RajuKucherlapati with million of people with genetic and medical information — searches of profile too group patients for optimal of with DB of – IBM

  19. @RajuKucherlapati Detection at pre-natal stages of multiple fetal disorders, abnormality, diagnosis drive treatment – genetic testing critical in cost Cardiomayopaty: in Young athlete genetic disorder

  20. Sajeev Kohli (11th Grade, Waterloo, On, Canada)Receives Top Honor at International BioGENEius Challenge Students from California, Washington and Germany named runners-up June 5, 2018 – Boston, Massachusetts –

  21. @TimothyBelski Joint Program Executive Office for Chemical and Biological Defense Manufacturing for DoD Infrastructure to manage across Government RFP Process

  22. We cover this event in Real Time

  23. Aviva Lev-Ari Retweeted MassBio

    BRAVO MA the of

    Aviva Lev-Ari added,

  24. Aviva Lev-Ari Retweeted JNJ Innovation

    Interested Chief Scientific Officer

    Aviva Lev-Ari added,


Re-Tweets and Likes by @Pharma_BI and by @AVIVA1950 from #BIO2018 @IAmBiotech @BIOConvention – BIO 2018, Boston, June 4-7, 2018, BCEC

Curator: Aviva Lev-Ari, PhD, RN


  1.   Retweeted

    Aviva Lev-Ari Retweeted Jeff Galvin

    Well put I agree with you, Jeff

    Aviva Lev-Ari added,

  2.   Retweeted

    Aviva Lev-Ari Retweeted I Am Biotech

    Aviva Lev-Ari added,

  3. Aviva Lev-Ari Retweeted Christiane Truelove

    BRAVO FDA in 2018 is AGILE

    Aviva Lev-Ari added,

  4. Aviva Lev-Ari Retweeted CCAB

    ASCO weigh in on CAR-Ts versus bispecific antibodies

    Aviva Lev-Ari added,

  5. Aviva Lev-Ari Retweeted Dana-Farber News

    Aviva Lev-Ari added,

  6. Aviva Lev-Ari Retweeted Jim Greenwood

    BRAVO inaugural Henri A. Termeer Biotechnology Visionary Award

    Aviva Lev-Ari added,

  7. Aviva Lev-Ari Retweeted JNJ Innovation

    Aviva Lev-Ari added,

  8.   Retweeted

    The 2018 Bio International Convention has been amazing! This was the view from our water taxi ride to the hotel last night! 🚤🛳🛥⛵️

  9. Aviva Lev-Ari Retweeted Ozmosi

    Aviva Lev-Ari added,

  10. Aviva Lev-Ari Retweeted Sanofi US

    BRAVO Sanofi

    Aviva Lev-Ari added,

  11. Aviva Lev-Ari Retweeted Sue Desmond-Hellmann

    HEROS for cure

    Aviva Lev-Ari added,

  12. Aviva Lev-Ari Retweeted BIO Intl Convention

    Aviva Lev-Ari added,

  13. Aviva Lev-Ari Retweeted Noy Kaufman

    Aviva Lev-Ari added,

  14. Aviva Lev-Ari Retweeted Business Sweden Invest

    Aviva Lev-Ari added,

  15. Aviva Lev-Ari Retweeted Alaric DeArment

    Aviva Lev-Ari added,

  16. Aviva Lev-Ari Retweeted Mike Huckman

    Aviva Lev-Ari added,

  17. Aviva Lev-Ari Retweeted JNJ Innovation

    Aviva Lev-Ari added,

  18. Aviva Lev-Ari Retweeted Elizabeth Cutler

    Aviva Lev-Ari added,

  19. Aviva Lev-Ari Retweeted Sanofi US

    BRAVO Sanofi, so smart to have bought Genzyme

    Aviva Lev-Ari added,

  20. Aviva Lev-Ari Retweeted Biotech Institute

    BRAVO Challenge!

    Aviva Lev-Ari added,

  21. Aviva Lev-Ari Retweeted IAM Platform

    Aviva Lev-Ari added,

  22. Aviva Lev-Ari Retweeted Sema4

    Aviva Lev-Ari added,

  23. Aviva Lev-Ari Retweeted Worldwide Clinical

    Aviva Lev-Ari added,

  24. Aviva Lev-Ari Retweeted Lori Collins

    ‘Largest Business Partnering Event’! Proud to cover the event in

    Aviva Lev-Ari added,

  25. Aviva Lev-Ari Retweeted Mike Huckman

    Aviva Lev-Ari added,

  26. Aviva Lev-Ari Retweeted Cleveland Scott York

    45,000 Partening sessions – BRAVO !!

    Aviva Lev-Ari added,

  27. Aviva Lev-Ari Retweeted Thermo Fisher G.R.

    Aviva Lev-Ari added,

  28. Aviva Lev-Ari Retweeted The Global IP Center

    Aviva Lev-Ari added,

  29. Aviva Lev-Ari Retweeted NHS Research Scotland

    BRAVO Scotland in

    Aviva Lev-Ari added,

  30. Aviva Lev-Ari Retweeted Quanterix

    BRAVO landscape in in light of

    Aviva Lev-Ari added,

  31. Aviva Lev-Ari Retweeted Vanitha Sekar

    made by Bill & Melinda Gates Medical Research Institution most nobel cause

    Aviva Lev-Ari added,

  32. Aviva Lev-Ari Retweeted HLC

    in Medicine

    Aviva Lev-Ari added,

  33. Aviva Lev-Ari Retweeted BlueCloud

    BRAVO Argentine

    Aviva Lev-Ari added,

  34. Aviva Lev-Ari Retweeted NFIA North America

    BRAVO Holland! places Holland No. 1 in the world for medical technology patents!

    Aviva Lev-Ari added,

  35. Aviva Lev-Ari Retweeted Intract Pharma

    Amazing COnference

    Aviva Lev-Ari added,

  36. Aviva Lev-Ari Retweeted MacBioCom

    Aviva Lev-Ari added,

  37. Aviva Lev-Ari Retweeted Hassan Naqvi

    meets INDUSTRY: BIOTECH & PHARMA with success

    Aviva Lev-Ari added,

  38. Aviva Lev-Ari Retweeted IN-PART

    INDEED, the best conference I have attended since 2013 when I cover in Real Time conferences as

    Aviva Lev-Ari added,

  39. Aviva Lev-Ari Retweeted JNJ Innovation

    BRAVO J&J for your broad spectrum in

    Aviva Lev-Ari added,

  40. Aviva Lev-Ari Retweeted Penny Heaton

    MOST NOBEL cause by MRI can be a catalyst to address urgent global health

    Aviva Lev-Ari added,

  41. Aviva Lev-Ari Retweeted I Am Biotech

    bRAVO I Am Biotech

    Aviva Lev-Ari added,

  42. Aviva Lev-Ari Retweeted ARMI

    BRAVO Aussi

    Aviva Lev-Ari added,

  43.   Retweeted

    Fireside chat with at

  44.   Retweeted

    Jeff Galvin, CEO of Rockville-based presented his company’s innovations in therapies for HIV, phenylketonuria, and cancer at . After the presentation, he was mobbed by potential investors and partners!

  45.   Retweeted

    How do you schedule hundreds of meetings all at once? has it figured out. Meeting many great potential supporters.

  46.   Retweeted

    It doesn’t get more epic than this l! The QUEEN, DIANA ROSS!

  47.   Retweeted

    Absolutely inspiring group of advocates on the patient voice panel. I feel honored to be in the room with them, listening to their remarkable stories and insights.

  48.   Retweeted

    Board of Directors Chair on diversity in during his Fireside Chat

  49.   Retweeted

    And for more on-the-ground analysis while you’re at , sign up for our daily newsletter, BIO in 30 Seconds.

  50.   Retweeted

    THURSDAY: (yes, twice!), 9:00am, 259B, on biotech’s data tsunami

  51.   Retweeted

    TUESDAY: , 4:15pm, 259A, on a new era of biotech journalism

  52.   Retweeted

    TUESDAY: , 1:45pm, 210B, on how to apply the lessons of immunotherapy from cancer to other diseases.

  53.   Retweeted

    MONDAY: , 4:00pm, 210A, talking how to cut waste between big pharma and payers in precision medicine.

  54.   Retweeted

    MONDAY: , 1:00pm, 206AB, talking what drug hunters look for in early stage assets.

  55.   Retweeted

    MONDAY: , 12:30pm at , talking best practices for co-working in the life sciences. (From the archives)

  56.   Retweeted

    THREAD: STAT is all over . Here’s where to find us.

  57.   Retweeted

    speaking with the member delegation at We’ve come to share with the world the excellence of our life science community in Canada.

  58.   Retweeted

    Team Queensland ready to showcase our state’s fantastic capabilities in all things biotech in Boston

  59.   Retweeted

    kicks off tomorrow in Boston, MA. Dr Glenn Begley, CEO and Linda Peterson, COO will be attending. DM us if you would like to connect with them.

  60.   Retweeted

    Heading to my first BIO convention, the rain can’t stop my excitement! 😁

  61.   Retweeted

    Proud to sponsor . We at love supporting and their missions to improve our health! See you at as we keep the startup celebration going tomorrow night! BIOGA25 for $25 GA tix

  62.   Retweeted

    Our friends at have put together the ultimate guide to the (). It features a complete list of conferences, private events/receptions, plus much more, all happening throughout the week. Get it here >>

  63.   Retweeted

    Through Pfizer Ventures, we plan to invest $600M in innovative science, with approximately $150M specifically targeted toward neuroscience. Join us at to learn more:

  64.   Retweeted

    “It will take you 10-15 years to get a breakthrough, but if you don’t start, you’ll never get there,” says J&J’s CSO Paul Stoffels when asked about at – at Boston Convention & Exhibition Center

  65.   Retweeted
  66.   Retweeted

    Great Q on driving (innovation in) “Huge opportunity in partnering with Pharma, not in replacing them, mainly due to the complexity of

  67.   Retweeted

    Penny Heaton Retweeted BIO Intl Convention

    Looking forward to next week, where we’ll have the opportunity to formally introduce the Gates MRI and share the mission, vision, and values behind the work we’re doing to accelerate product development for diseases that disproportionately affect the world’s poorest.

    Penny Heaton added,

  68.   Retweeted

    Attending ? These SECRET STAIRS, only minutes from the convention center, lead to our local Fort Point restos, breweries and more!

  69.   Retweeted

    At … it’s like Epcot in here! So many countries and states courting the bio biz.

  70.   Retweeted

    the best way to conclude this incredible !!!

  71.   Retweeted

    Making History in Boston.

  72.   Retweeted

    At biggest biopharma partnering event in the world, scale is pretty amazing…

  73.   Retweeted

    I can’t believe attendees are told by conference organizers that “locals” recommend: “Let loose and explore the nightlife of Boston, grab a couple beers at the iconic “Cheers” bar.” Let me qualify that: NOBODY IN THIS CITY WOULD RECOMMEND THAT.

  74.   Retweeted

    How cool is this new tool from ?! It provides info on partnering opportunities and contacts for over 60+ patient advocacy groups. Very useful!

  75.   Retweeted

    And here it is, the most famous Paul Stoffels quote we hear ALL THE TIME at “You take the risk and I take the blame” in

  76.   Retweeted


  77.   Retweeted

    . – tonight, Karl-Rudolf Erlemann of was all of us.

  78.   Retweeted

    Which biopharmaceutical companies are making a real difference for patients? Our CSO Michael Severino explains how to spot R&D leaders.

  79.   Retweeted

    Had to get to the front row for the encore at live!

  80.   Retweeted

    There is till time to visit us at , booth 1344. If you require nucleosides and carbohydrates for your business, come to speak to our specialist – maybe we can help.

  81.   Retweeted

    Thank you and for helping me meet a real life superhero. Ashanti DeSilva the first person in the world treated with 28 years ago. A passionate , advocate and a personal inspiration

  82.   Retweeted

    Wonderful to meet Baroness Fairhead CBE, Minister of State at DIT on the UK Pavilion at

  83.   Retweeted

    The expo floor is a trip around the world of innovation!

  84.   Retweeted

    Great reception at Startup Stadium today. It’s been a great week here in Boston.

  85.   Retweeted

    No rest for attendees! It’s the last day of Convention, but the action isn’t slowing down yet. Look out for these featured events in today’s schedule:

  86.   Retweeted

    It was another history-making ! We look forward to hosting you in on 2019 to make even more history!

  87.   Retweeted

    Pitt has once again surpassed its records for startups in fiscal 2019 with 21 companies spun out of the university. Could a Pitt startup be your next entrepreneurial or investment opportunity?

  88.   Retweeted

    I will survive! ⁦ very Darwinian!

  89.   Retweeted
    Replying to 

    No “jail” means being forced to listen to speak at . I hope he’s wearing cool socks.

  90.   Retweeted

    Don Seiffert Retweeted Suzanne Fraser

    Diana Ross performing “I Will Survive” at the Convention Center for

    Don Seiffert added,

  91.   Retweeted

    Agendia Retweeted PMC

    Thanks for inviting our CMO, Dr William Audeh, to join this important and timely in Action panel at

    Agendia added,

  92.   Retweeted

    Last day for and last chance to meet 10 companies from and health cluster. Visit us on booth 527, France pavilion.

  93.   Retweeted

    Still time to visit us at booth 1753

  94.   Retweeted

    Find and meet our BD Manager Emmanuelle Astoul who is attending in Boston to talk about collaboration opportunities with

  95.   Retweeted

    Today last day! Come visit us at booth #1328 and enjoy some argentinian alfajores and coffee!

  96.   Retweeted

    Today at 10:30am, join our Senior Investment Director, Dr. Karen Hong at for “Business Development & Finance: An Investor’s Perspective on Value of New Biotherapeutics” in Room 252AB, Level 2.

  97.   Retweeted

    Fun session y’day at on drug prices, R&D cost, and innovation – many thanks to & ! Good convo abt whether (a) competition will ⬇️ prices in cancer and rare dz, & (b) NIH, prizes, etc. can sustain & focus Rx innovation in the future.

  98.   Retweeted

    Speak to our Team on the UK Pavilion (stand 1333) at the Bio International Convention

  99.   Retweeted

    Want to learn more about collaboration between and JPEO-CBRND? Stop by booth 1913 to learn more and how Industry can engage with us.

  100.   Retweeted

    Home stretch! Day 4 begins with business development first thing in the morning. .

  101.   Retweeted

    Last day of kicks off with fireside chat in one hour

  102.   Retweeted

    At Shares the Journey: being an award-winning broadcast journalist and author, and a survivor of breast cancer and myelodysplastic syndrome (MDS),

  103.   Retweeted

    Over the past 21 years, we’ve forged long-term, mutually successful partnerships, bringing innovations and solutions together to meet the worlds healthcare needs. Connect with us at the Scottish Pavillion to discover what we can do for your clinical trial journey.

  104.   Retweeted

    ⁩ hosted a great alumni networking event around

  105.   Retweeted

    Rob Reiner and I will be joining you on stage shortly!

  106.   Retweeted

    Are you at ? Be sure to stop by Booth #2101 to learn more about the 10 remarkable Israeli companies, spanning the spectrum of ’s vigorous Life Sciences community- from innovative start-ups to established companies!

  107.   Retweeted

    Great discussion at today’s “Best Practices for Working with Patient Advocacy Organizations,” with our own Jessica Riviere, Senior Director, Biogen

  108.   Retweeted

    We are excited to have , CEO of with us live at the Massachusetts pavilion speaking live

  109.   Retweeted

    Our President of R&D Akshay Vaishnaw took the stage earlier today at the pavilion to tell our innovation and Massachusetts story. therapeutics

  110.   Retweeted

    Standing ovation for Ashanthi De Silva at ! “Have hope, be your own advocate, and never give up.” – at Boston Convention Center Grand Ballroom

  111.   Retweeted

    Diversity and inclusion is an BoD priority, an priority and my priority. During my fireside chat w/ Halozyme CEO Helen Torley today at , I committed to not participate in any future panel that is not diverse.

  112.   Retweeted

    Here in Massachusetts, innovation is a way of life. It truly is the . If you want it to happen, you need to be here – Massachusetts is the place where life sciences companies can find the people, the ideas and the resources they need to innovate and grow. – at Boston Convention & Exhibition Center

  113.   Retweeted

    We OFFICIALLY made history this week! BIO’s Joanne Duncan accepting our Guinness World Record for ‘Largest Business Parneting Event’

  114.   Retweeted

    Excited to hear member and Reg Affairs Committee member Kelli Tanzella of give her perspective on the regulatory paradigm for NGS panels.

  115.   Retweeted

    Trailblazing discoveries in health sciences are what we do here.

  116.   Retweeted

    Did you know that every 3.5 minutes someone will die from lung cancer? Boston University and investing in changing this

  117.   Retweeted

    We did it! We set a world record for the Largest Business Partnering Event. Thank you to everyone!

  118.   Retweeted

    I’ve been around the world twice. is the Epcot of Bio, Science & Pharma companies. Proud to see companies recognizing the Making great connections to support our students.

  119.   Retweeted

    Eager to elevate the & voice at this morning’s panel discussion on Communicating Value Through the Eye of the Beholder

  120.   Retweeted

    Need for evidence of PM’s value has emerged as & Dx Track” theme. Now, , , reps show / parallel review pathway, joint studies by commercial insurers/Dx companies will be key.

  121.   Retweeted

    The winner of Dr. Paul Janssen Award Jim Allison discusses the importance of elevating science to a household conversation if we want to improve our collective health.

  122.   Retweeted

    Congrats to for setting the Guinness World Record for largest business partnering event!

  123.   Retweeted

    Diversity and inclusion in science goes beyond who’s at the bench and all the way to who the science serves – 80% of NIH’s genomic data that’s used to push forward precision medicine is from people of European descent. (That’s not okay)

  124.   Retweeted

    speed networking is happening now! Booth #2001

  125.   Retweeted

    Honored to have had the opportunity to address this morning and talk about how real, palpable ultimately means real, palpable patient impact!

  126.   Retweeted

    We don’t do germline editing; society is not at a place to be ready for this, also it’s against recs, says Sandy Macrae . Carrie Wolinetz agrees, says term distinction is crucial, confusing these can feed back into regulatory framework detrimentally.

  127.   Retweeted

    What question would you ask at a discussion about the regulatory framework in human genome editing?

  128.   Retweeted

    “One patient at a time, positive responses are demonstrating that RNAi technology indeed has the potential to bring about a paradigm shift in medicine,” writes Mano Manoharan, SVP, Innovation Chemistry, in a blog post discussing our journey to advance therapeutics.

  129.   Retweeted

    The opportunities to advance the clinical trial model with personalized and targeted approaches are endless, from in the

  130.   Retweeted

    Fantastic dialogue going on in 204AB at . Completely candid remarks from tremendous group

  131.   Retweeted

    It was great to meet Jim Greenwood, CEO of at . – Robert Naismith, Chairman

  132.   Retweeted

    Wow knows how to put a stellar diverse panel together 🙌

  133.   Retweeted

    Front and center, Maryland is in a prime position to move business and innovation forward!

  134.   Retweeted

    This is a loaded panel & plenty of seats avail. Turbo charge R&D activities in 252AB

  135.   Retweeted

    Q to panel as public co CEOs – how do you investor risk? Dahiyat says people will invest if they think co. will make money either way. Hastings says will push some away, draw others in, so do what’s right.

  136.   Retweeted

    Our Biocom team has been taking full advantage of making ALL the connections at ! Check us out at the California Pavilion or stop by Startup Stadium tomorrow where we’ll be supporting our member !

  137.   Retweeted

    For those interested in learning more about gene-based therapies, make sure to attend the “Making Genetic Therapies a Reality for Patients” panel featuring our Chief Commercial Officer, Emmanuel Dulac.

  138.   Retweeted

    & Dx Track” has showed progress on several policy fronts. But , , reps say providers are still not incentivized to deliver holistic, value-based medicine. Reimbursement paradigms must evolve, they say.

  139.   Retweeted

    Travis McCready from closes out the Possible Talks at in the – “The only way that this industry will evolve, the only way we’ll find cures, is to develop the next generation of diverse talent and to break the mold.” That’s a wrap!

  140.   Retweeted

    “Breakthrough cience occurs when you cross disciplines” Mikael Dolsten

  141.   Retweeted

    🛑! Working on a slide deck to communicate your awesome 🔬? Here are some presentation basic design tips 🎨 for this week’s !

  142.   Retweeted

    Representatives from European biotech, regulatory and venture capital describe the state of investments in Europe and how global participants can get involved

  143.   Retweeted

    Great to meet Australia’s top medical entrepreneurs, discussing how they can take their successful ideas global, creating more jobs and improving patient outcomes

  144.   Retweeted

    Biologos is having a great time at this week in Boston!

  145.   Retweeted

    Great panel at on Digiral Medicines with leaders of of of Marisa Cruz of and Mostafa Kamal of Magellan

  146.   Retweeted

    Great points from re patient consent, consent for life, by Sandy Macrae, and need to ensure patients truly understand what it is they are committing to

  147.   Retweeted

    Q based on diversity training: anybody willing to do training similar to Starbucks? Dahiyat says his company already diverse, but reaches out to area to encourage diversity in science. Johnson says similar program at Dare – get more diversity in science with local youth.

  148.   Retweeted

    Over a 7-year period biotech job growth outpaced national growth by 14% Visit to find out why call home

  149.   Retweeted

    Life sciences companies aren’t innovating processes with and other technologies, but whoever tackles this first will win. from leads a discussion at with leaders from , , , and .

  150.   Retweeted
  151.   Retweeted

    Independent test results confirm the new VIP ECO upright ultra-low temperature freezer has the lowest total daily energy usage in its class in the industry. Visit us at this week Booth 1927 to learn more. Download your white paper here:

  152.   Retweeted

    DrugDeliveryExperts Retweeted BIO Intl Convention

    And DDE was there… Congrats to !

    DrugDeliveryExperts added,

  153.   Retweeted

    Save the date… reminding everyone at to come visit us next year in !

  154.   Retweeted

    Some impressions representing trends on : , driving the funnel and from all over the world – at Boston Convention & Exhibition Center

  155.   Retweeted

    “Europe is a uniquely attractive place for biotech”; lively discussion at our session on Europe’s value proposition for + investment

  156.   Retweeted

    Dahiyat continues: If you are running your business in a way that is profitable, investors won’t care. If not, it doesn’t matter if you’re silent anyway.

  157.   Retweeted

    Thank you for joining today’s panel with and the and for working with us to bring the patient viewpoint forward in value assessment.

  158.   Retweeted

    Now on stage at former MA governor ; extremely inspiring and a good example that a strong political vision is a key to Life Sciences Cluster development

  159.   Retweeted

    Hats off to — Been coming for most of the last 15 years, and I’ve never seen this level of buzz about business, doing things, in . Congrats on a job well done.

  160.   Retweeted

    Today Paul Stoffels, CSO of will be discussing new strategies for the development of & for the developing world. If you’re at head to Room 251, Level 2 at 3:00pm.

  161.   Retweeted

    Fireside Chat speaker and BIO Board of Directors chair on diversity and business

  162.   Retweeted

    THE is performing LIVE at TONIGHT at the BCEC! You must have a Convention Access badge to enter, and warning: space is extremely limited. Admittance is first-come, first-served, so make sure to arrive early! Thanks to our sponsors

  163.   Retweeted

    WIB Pittsburgh Retweeted Women In Bio

    For those of you at , check this out!

    WIB Pittsburgh added,

  164.   Retweeted

    Mark your calendars! Chief Scientific Officer Paul Stoffels will sit down with founder on Monday at 4pm at to discuss how we can speed innovation in science and medicine.

  165.   Retweeted

    I believe in dreaming big and focusing small ~ great words to live by. BIOConvention

  166.   Retweeted

    So much going on today at ! Keynotes from industry leaders, panels on cutting edge research, and 1×1 partnering now happening in the Business Forum!

  167.   Retweeted

    To all who will be attending this week, a very warm welcome to my adopted hometown…AKA “The City of Champions” (in case you’ve forgotten!).

  168.   Retweeted

    As an industry, we will continue to champion the evolution of “patients as subjects” to “patients as partners.” They’re the real experts in their conditions. They’re following the research. They’re clinical pioneers. And they’re our real-life inspirations.

  169.   Retweeted

    Enjoyed dinner w/ cool and fun power women Cat Oyler, Suzy Lebold Sue Dillon, Reema Driscoll

  • More than 77 percent of patients in the REMfresh® Patient Reported Outcomes DURation (REMDUR) study reported achieving 6 or more hours of sleep after taking REMfresh®, the first continuous release and absorption melatonin (CRA-melatonin)
  • More than 91 percent experienced improvements in sleep onset, sleep maintenance and total sleep quality, after taking REMfresh® (CRA-melatonin)
  • Post-marketing, patient-reported outcomes data reinforces clinical trial evidence demonstrating the potential of non-prescription REMfresh®, as a new, non-prescription, drug-free hypnotic (sleep) product designed to achieve 7-hour sleep
  • New data confirms previously presented SLEEP 2017 study showing the patented Ion Powered Pump (IPP) technology in REMfresh® helps extend melatonin-targeted sleep maintenance levels in the body from 3.7 hours (with marketed immediate-release melatonin) to 6.7 hours, while mimicking the pattern of the body’s natural melatonin blood levels during the nightly sleep cycle

Real Time Coverage at SLEEP 2018 meeting, Baltimore.

Reporters: Aviva Lev-Ari, PhD, RN, and Gail S. Thornton, MA

BALTIMORE – (June 6, 2018) – A patient-reported outcomes study presented at SLEEP 2018 provides confirmatory real-world evidence of the previously peer-reviewed and presented data showing the 7-hour action of REMfresh®, a new product for sleep. REMfresh® Ion-Powered Melatoninis the first and only, continuous release and absorption melatonin (CRA-melatonin) to mimic the body’s own 7-hour Mesa Wave, the natural pattern of melatonin blood levels during a normal night’s sleep cycle. This induces sleep onset and provides lasting and restorative sleep for up to 7 hours.

This new data shows a correlative relationship between a 7-hour Mesa Wave pharmacokinetic (PK) profile and real-world evidence of improvements in sleep duration, onset, maintenance and sleep quality after taking REMfresh® (CRA-melatonin).

The post-marketing REMfresh® Patient Reported Outcomes DURation (REMDUR) study was presented at SLEEP 2018, the 32nd Annual Meeting of the Associated Professional Sleep Societies (APSS), LLC, a joint partnership of the American Academy of Sleep Medicine (AASM) and the Sleep Research Society (SRS).


Brodner and Seiden

Pictured here is David C. Brodner, M.D., and David J. Seiden, M.D., FAASM, after presenting the latest study data which found REMfresh is the first and only continuous release and absorption melatonin™ to mimic the body’s own 7-hour Mesa Wave™.


In a sample of 500 patients on REMfresh® (CRA-melatonin) responding to an online survey, 77.6 percent achieved 6 or more hours of sleep compared to 23.6 percent who slept that duration prior to taking REMfresh® (p<.0001). A vast majority of respondents also reported a major or moderate improvement in sleep onset (91.6 percent, p<.0001), sleep maintenance (94.8 percent, p<.0001) and total sleep quality (97.2 percent, p<.0001). More than three-quarters (76.6 percent) of patients indicated they take REMfresh® (CRA-melatonin) nightly. The proportion of patients reporting nightly CRA-melatonin use was significantly greater than the proportion of patients with less than nightly use (p<.0001). Most importantly, over 98 percent of patients reported they were very likely or likely to continue taking REMfresh® (CRA-melatonin) to treat their sleep complaints.

“The real-world evidence reported today in REMDUR provides further confirmation that REMfresh® represents a significant advance in the use of melatonin as a baseline therapy for treating sleep complaints,” said David C. Brodner, M.D., a leading sleep specialist who is Double Board-Certified in Otolaryngology — Head and Neck Surgery and Sleep Medicine, founder and principle Physician at the Center for Sinus, Allergy, and Sleep Wellness, in Palm Beach County, Florida, and Senior Medical Advisor for Physician’s Seal, LLC®.

“REMfresh® Ion-Powered Melatoninhas been shown to be an effective drug-free solution that is now available to the millions of Americans in need of a good night’s sleep, many of whom seek new therapies that will induce sleep and keep them asleep until the morning, without causing residual effects they’ll feel the next day. With its unique delivery system that imitates the body’s own natural sleep pattern, REMfresh® has revolutionized the role of melatonin, when delivered in the CRA form. It is no longer just a treatment for jet lag, but the CRA-melatonin found in REMfresh® has been shown to provide substantial relief to individuals having nightly sleep challenges,” said Dr. Brodner.

The scientifically advanced, patented delivery system in REMfresh® (CRA-melatonin), called Ion Powered Pump (IPP™) technology, replicates the way in which the body naturally releases and absorbs melatonin, unlike conventional melatonin sleep products. Since REMfresh® is not a drug, there is no drug hangover.

Nearly one-third of U.S. adults sleep less than the recommended seven hours daily.[1],[2] Increasing evidence suggests an association between sub-optimal sleep duration and adverse health outcomes including a higher risk of diabetes, hypertension, heart attack, stroke, obesity and depression.[3] A pooled analysis of 16 studies and over one million patients found short sleep duration corresponded with greater risk of morbidity and mortality.[4]

 REMDUR Study Design

The post-marketing REMfresh® Patient Reported Outcomes DURation (REMDUR) study was designed to obtain real-world evidence about patients’ sleep patterns, duration of sleep before and after REMfresh® (CRA-melatonin), daily REMfresh® (CRA-melatonin) use, onset of action, sleep maintenance, quality of sleep, and overall satisfaction with REMfresh® (CRA-melatonin).

Patients with sleep disturbances in the general population who received a sample of CRA-melatonin (REMfresh®) from their physicians were invited to complete a 12-question survey. Survey responses were received from 500 patients.

Confirmation of the REMAKT Clinical Study

REMDUR confirmed clinical trial findings from REMAKT (REM Absorption Kinetics Trial), a U.S.-based randomized, crossover pharmacokinetic (PK) evaluation study in healthy, non-smoking adults that compared REMfresh® (CRA-melatonin) with a market-leading, immediate-release melatonin (IR-melatonin).[5]

The study results, peer-reviewed and presented last year at SLEEP 2017, showed that melatonin levels with REMfresh® (CRA-melatonin) exceeded the targeted sleep maintenance threshold for a median of 6.7 hours, compared with 3.7 hours with the leading IR-melatonin. Conversely, the levels of the market-leading IR-melatonin formulation dramatically increased 23 times greater than the targeted levels of exogenous melatonin for sleep maintenance and had a rapid decline in serum levels that did not allow melatonin levels to be maintained beyond 4 hours.

The REMfresh® (CRA-melatonin) studies build upon the body of evidence from prolonged-release melatonin (PR-M), marketed in Europe, which demonstrated in well-conducted, placebo-controlled studies, statistically significant improvement in sleep quality, morning alertness, sleep latency and quality of life in patients aged 55 years and older compared with placebo. REMfresh® (CRA-melatonin) was designed to overcome the challenges of absorption in the intestines, thereby extending the continual and gradual release pattern of melatonin through the night (known as the Mesa Wave, a flat-topped hill with steep sides). There was a fast time to Cmax, which is anticipated to result in improved sleep onset, while the extended median plateau tim